Psychemedics Corporation
Psychemedics Corporation provides hair sample analysis testing services for drug detection and health markers globally. They offer screening and confirmation tests for various substances, including cocaine, marijuana, opioids, synthetic cannabinoids, benzodiazepines, nicotine, fentanyl, and alcohol. Their tests provide quantitative data on drug intake and historical usage patterns. The company serves employers, treatment professionals, law enforcement agencies, school administrators, and parents to detect drug use in job applicants, employees, and children.
Overview
Strengths
- Price to book ratio (2.63) is lower than the sector mean (9.96).
- Analysts expect revenues to grow in the coming year.
- Price to free cash flow (16.03) is lower than the sector mean.
Weaknesses
- With a depreciation Potential of -100.00%, based on our fundamental analysis, it suggests the stock may be overvalued.
- Current Price to Earnings Ratio (100.00) is significantly higher than the sector mean (67.88).
- The company has high debt. Net Debt to EBITDA Ratio (7.79) is higher than the sector mean.
- EV/EBITDA (77.72) is significantly higher than the sector mean (36.02).
- EV/EBIT (100.00) is significantly higher than the sector mean.
- EBITDA Margin (0.99%) appears relatively low.
Key Financial Data
| Indicator | Value |
|---|
| PER | 100.0 |
| EV/EBITDA | 77.7 |
| Price/Free Cash Flow' | 16.0 |
| ROIC | 11.5% |
| Net Debt/EBITDA | 7.8 |